EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study

Laura Butragueño-Laiseca, Gastón García-Orueta, Natalia Riva, Iñaki F Trocóniz, Sarah N Fernández, Verónica Camacho Vicente, Belén Padilla, María Slöcker, María José Santiago iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf012 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Laura Butragueño-Laiseca und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Intensive Care Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Teicoplanin, Anti-Bacterial Agents, Continuous Renal Replacement Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Carlos III Institute of Health, European Regional Development Fund, Research Network: Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Development Origin Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Teicoplanin is a commonly used antibiotic in critically ill children. However, teicoplanin dosing is often inaccurate, especially in children undergoing continuous kidney replacement therapy (CKRT). This study aims to develop a population pharmacokinetic (PK) model to optimize teicoplanin dosing in critically ill children, including those on CKRT.

Methods

Data from 26 critically ill children (12 with CKRT) receiving the standard dosing regimen were analysed. In total, 172 teicoplanin concentration measurements from plasma, pre- and post-filter ports were modelled simultaneously using NONMEM 7.4. Simulations were conducted to assess the target attainment (Cmin = 10 mg/L and AUC24/MIC > 800 h) of the current standard dosing regimen and of different alternative dosing regimens.

Results

A two-compartment model was selected. Weight significantly affected renal clearance and volume of distribution of the central compartment, while filter surface area affected haemofilter clearance. Only 16 patients (59%) achieved a Cmin of >10 mg/L with the standard dosing regimen, and only 1 achieved the target AUC/MIC. Based on simulation results, 3 × 15 mg/kg q12h + 10 mg/kg q24h (CKRT) and 3 × 15 mg/kg q12h + 15 mg/kg q24h (no CKRT) could be better alternative regimens.

Conclusions

This population model is a good proof of concept to develop modelling approaches that could help in an individualized dosing approach that needs to be adopted in critically ill paediatric patients. The standard paediatric dosage for teicoplanin could be insufficient for optimal exposure, and higher doses may benefit both CKRT and non-CKRT patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TeicoplaninAnti-Bacterial AgentsContinuous Renal Replacement TherapyHumansProspective StudiesChild, PreschoolMaleFemaleInfantChildCritical IllnessMicrobial Sensitivity TestsAdolescent

Substanzen

TeicoplaninAnti-Bacterial Agents

Autor:innen und Institutionen

  • Pediatric Intensive Care Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
  • Departamento de Salud Departamento de Salud Pública y Materno Infantil, Universidad Complutense de Madrid, Madrid, Spain.
  • Red de Investigación Cooperativa Orientada a Resultados en Salud (RICORS RD21/0012/0011), Institute of Health Carlos III, Madrid, Spain.
  • Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
  • Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.

ORCID-Profile: María José Santiago

Förderung

  • Carlos III Institute of Health
  • European Regional Development Fund
  • Research Network: Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Development Origin Network

Zitieren

APA

Butragueño-Laiseca, L., García-Orueta, G., Riva, N., Trocóniz, I. F., Fernández, S. N., Camacho Vicente, V., Padilla, B., Slöcker, M., & Santiago, M. J. (2025). Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf012

Vancouver

Butragueño-Laiseca L, García-Orueta G, Riva N, Trocóniz IF, Fernández SN, Camacho Vicente V, et al. Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf012

BibTeX
@article{ButragueoLaiseca2025,
  author = {Butragueño-Laiseca, Laura and García-Orueta, Gastón and Riva, Natalia and Trocóniz, Iñaki F and Fernández, Sarah N and Camacho Vicente, Verónica and Padilla, Belén and Slöcker, María and Santiago, María José},
  title = {Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf012}
}
Kostenlos starten →